Prof Roy Herbst speaks to ecancer about the abstract he presented at the 2020 ASCO Virtual Meeting on the results of the ADAURA trial.
The trial used osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection.
Prof Herbst discusses the impact of the highly promising results.
Read more about this research here.
This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.